
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
pmc: PMC9487233 , PMC6348356
handle: 2434/220247
Pulmonary hypertension (PH) is a frequent complication of left heart disease arising from a wide range of cardiac disorders. In the clinical classification, PH associated with left heart disease is classified as Group 2, which includes left heart systolic dysfunction, left heart diastolic dysfunction and left heart valvular disease. In the past, rheumatic mitral valve disease was the most common cause of PH in left heart disease; however, today it is more likely to be associated with hypertensive and/or ischaemic heart disease.As the incidence of these conditions is increasing, the number of patients presenting with PH is also increasing and, today, left heart disease represents the most frequent cause of PH. The development of PH in patients with left heart disease is associated with poor prognosis. However, despite the increasingly large number of patients affected and the impact of PH on outcome, there are currently no specific treatment options for these patients.This review gives an overview of the pathophysiology and epidemiology of PH associated with left heart disease, and discusses the challenges associated with its management and treatment.
Endothelin A Receptor Antagonists, Hypertension, Pulmonary, Vasodilator Agents, Nitric Oxide, left heart disease, Diseases of the respiratory system, Electrocardiography, pulmonary hypertension, post-capillary, Humans, Pulmonary Wedge Pressure, Left heart disease; Preserved ejection fraction; Pulmonary hypertension, Antihypertensive Agents, Sulfonamides, RC705-779, Endothelin-1, R, Bosentan, Stroke Volume, Phosphodiesterase 5 Inhibitors, preserved ejection fraction, Echocardiography, Doppler, congestive heart failure, pulmonary artery pressure, Left heart disease, Heart Valve Prosthesis, Commentary, Exercise Test, Medicine, Mitral Valve, Radiography, Thoracic, Vascular Resistance, pre-capillary, Endothelium, Vascular
Endothelin A Receptor Antagonists, Hypertension, Pulmonary, Vasodilator Agents, Nitric Oxide, left heart disease, Diseases of the respiratory system, Electrocardiography, pulmonary hypertension, post-capillary, Humans, Pulmonary Wedge Pressure, Left heart disease; Preserved ejection fraction; Pulmonary hypertension, Antihypertensive Agents, Sulfonamides, RC705-779, Endothelin-1, R, Bosentan, Stroke Volume, Phosphodiesterase 5 Inhibitors, preserved ejection fraction, Echocardiography, Doppler, congestive heart failure, pulmonary artery pressure, Left heart disease, Heart Valve Prosthesis, Commentary, Exercise Test, Medicine, Mitral Valve, Radiography, Thoracic, Vascular Resistance, pre-capillary, Endothelium, Vascular
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 98 | |
popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
views | 4 |